查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2008678

纖維肌痛治療市場：按藥物類別、給藥途徑、分銷管道和最終用戶分類的全球市場預測 – 2026-2032 年

Fibromyalgia Therapeutics Market by Drug Class, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，纖維肌痛治療市場價值將達到 38.5 億美元，到 2026 年將成長至 40.4 億美元，到 2032 年將達到 56.6 億美元，複合年成長率為 5.66%。

主要市場統計數據
基準年 2025 38.5億美元
預計年份：2026年 40.4億美元
預測年份 2032 56.6億美元
複合年成長率 (%) 5.66%

詳細介紹不斷發展的纖維肌痛治療市場，重點關注臨床複雜性、治療差距和策略重點。

纖維肌痛症是一種臨床表現複雜的症候群，其特徵是慢性、廣泛性疼痛、疲勞、睡眠障礙和認知症狀，這些症狀共同導致患者功能顯著受損，並給醫療保健系統帶來沉重負擔。臨床異質性和重疊的合併症（例如情緒障礙和慢性疼痛綜合症）使診斷和治療方法選擇更加複雜，凸顯了個體化治療路徑和多方面管理策略的重要性。在臨床實踐中，臨床醫生需要在藥物治療和非藥物治療之間取得平衡，以緩解症狀，同時最大限度地降低副作用和多重用藥的風險。

變革性的變化正在重塑纖維肌痛的治療，其手段包括以機制為中心的治療方法、數位化護理、適應性臨床試驗以及與保險公司不斷發展的合作。

近年來，一系列變革性的變化正在改變我們開發、評估和提供纖維肌痛治療的方式。科學進步正將治療重點從廣泛的症狀治療轉向基於神經生物學、針對特定通路的干涉措施，同時，適應性試驗設計和精細的受試者選擇策略正在加速我們在臨床相關人群中檢驗基於機制的假設。同時，數位療法和遠端監測工具的興起正在擴大非藥物治療的選擇範圍，這些選擇可以與藥物治療相結合，從而提供全面的護理。

本研究評估了 2025 年美國關稅措施將如何影響纖維肌痛治療的供應鏈、採購決策和發展策略。

政策干預，例如關稅調整，會對與治療藥物的研發和上市相關的營運和策略決策產生重大影響。美國2025年實施的關稅措施將成為纖維肌痛治療生態系中相關人員關注的關鍵因素。這些措施將影響活性成分、特殊輔料、用於神經調控和藥物輸送的醫療設備以及生物標記檢測所需的實驗室試劑的成本和供應。因此，申辦方和生產商需要重新審視籌資策略和庫存管理實踐，以應對供應鏈波動風險。

深入了解藥物類別趨勢、給藥途徑、分銷管道和最終用戶細分，有助於指導臨床和商業決策。

透過細分分析獲得的洞見揭示了臨床、商業性和營運選擇如何在定義纖維肌痛治療生態系統的多個維度上相互交織。藥物類別包括抗驚厥藥、選擇性血清素再回收抑制劑（SSRIs）、血清素-正腎上腺素再回收抑制劑（SNRIs）和三環抗憂鬱藥物。在這些類別中，抗驚厥藥又可進一步細分為品牌藥和選擇性血清素再回收抑制劑學名藥兩種選擇，類似的品牌藥與學名藥的動態也適用於SSRIs、 血清素-正腎上腺素和三環抗憂鬱藥物，這直接影響著藥物的生命週期規劃和價格競爭力。

針對全球纖維肌痛治療的管理體制、臨床應用、報銷模式和業務重點，提供區域性見解。

區域趨勢對纖維肌痛治療的發展重點、進入策略和商業化路徑有顯著影響，因此，採取因地制宜的方法至關重要。在美洲，法規結構和與支付方的談判中都強調療效和藥物經濟評估，而創新中心和成熟的契約製造網路則有助於快速改進產品並增強供應鏈的韌性。此外，美洲地區數位醫療解決方案的普及和病患支援活動的開展都在不斷推進，這有望加快分散式臨床試驗的受試者招募和整合式照護路徑的實施。

對創新者、專業開發公司、契約製造和數位供應商如何塑造纖維肌痛護理策略進行企業和競爭考察。

纖維肌痛治療領域企業的定位反映了創新主導研發公司、專業生物技術企業、契約製造和新興數位醫療供應商之間的互動。創新者專注於獨特的作用機制和更高的耐受性，以實現臨床差異化；而專業研發公司和平台公司則致力於探索可與藥物療法相結合的輔助療法，以應對纖維肌痛症狀帶來的多重負擔。契約製造和CDMO在確保複雜製劑的大規模生產和供應的可靠性方面發揮著核心作用，其能力在合作夥伴選擇和緊急時應對計畫中也變得日益重要。

為產業領導者提供切實可行的建議，以優先考慮供應鏈韌性、循證開發、支付方合作以及以患者為中心的商業化方法。

產業領導者應採取多管齊下的方法，增強供應鏈韌性，推動實證實踐，並將病患體驗置於商業化計畫的核心。首先，透過多元化關鍵原料藥和組件的供應商基礎、投資策略庫存緩衝以及定期進行供應商風險評估來強化供應鏈，從而預測採購中斷情況。其次，優先考慮整合患者報告結局（PRO）和功能性終點的研發項目，在適當情況下採用適應性或富集性試驗設計，並儘早與監管機構和支付方開展對話，以就可接受的證據包達成共識。

詳細的調查方法解釋了應用於纖維肌痛研究結果的數據來源、專家參與、真實世界數據 (REW) 方法以及分析的嚴謹性。

為支持這些發現，本研究採用了一種混合方法，將定性專家意見與定量證據來源和文獻分析相結合，以確保分析的嚴謹性和有效性。主要研究包括對臨床關鍵意見領袖、處方集決策者、採購專家以及在纖維肌痛領域開展專案的開發人員進行結構化訪談，從而觀點真實世界的治療模式、證據預期和運營限制。次要資訊包括同行評審的臨床文獻、監管申報文件、臨床試驗註冊資訊以及公開的臨床和安全資料儲存庫，從而對作用機制和療效訊號進行背景分析。

總結整合，強調將臨床、商業性和政策措施整合起來，以加速顯著改善纖維肌痛患者的照護結果。

總之，纖維肌痛的治療正處於一個轉折點，其特徵是對疾病機制有了更深入的了解，對證據的期望發生了轉變，以及受政策和供應方面因素影響而導致的運營環境變化。有效的應對措施需要將治療方案的發展與以患者為中心的終點指標相結合，投資於互補的數位化和行為療法解決方案，並保持供應鏈的靈活性以應對政策變化。臨床醫生、保險公司和研發人員必須通力合作，共同製定有意義的療效指標，並制定能夠獲得監管部門核准和保險公司認可的實證方案。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 纖維肌痛治療市場：依藥物類別分類

  • 抗驚厥藥物
    • 品牌商品
    • 非專利的
  • 選擇性血清素再回收抑制劑
    • 品牌商品
    • 非專利的
  • 血清素-正腎上腺素再回收抑制劑
    • 品牌商品
    • 非專利的
  • 三環抗憂鬱藥物
    • 品牌商品
    • 非專利的

第9章：纖維肌痛治療市場：依給藥途徑分類

  • 口服
  • 腸外
  • 外用

第10章：纖維肌痛治療市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第11章 纖維肌痛治療市場：依最終使用者分類

  • 居家照護
  • 醫院
  • 專科診所

第12章 纖維肌痛治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 纖維肌痛治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 纖維肌痛治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國纖維肌痛治療市場

第16章：中國纖維肌痛治療藥物市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • Amicus Therapeutics
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc
  • CH Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline（GSK）
  • Jazz Pharmaceuticals plc
  • Johnson & Johnson Services, Inc.
  • Kyowa Kirin Co, Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi SA
  • Sarepta Therapeutics, Inc.
  • Takeda Pharmaceutical Company
  • Teva Pharmaceutical Industries Ltd.
  • The Bristol-Myers Squibb Company
  • Vertex Pharmaceuticals Incorporated
  • Viatris inc.
Product Code: MRR-8E22B61932B5

The Fibromyalgia Therapeutics Market was valued at USD 3.85 billion in 2025 and is projected to grow to USD 4.04 billion in 2026, with a CAGR of 5.66%, reaching USD 5.66 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.85 billion
Estimated Year [2026] USD 4.04 billion
Forecast Year [2032] USD 5.66 billion
CAGR (%) 5.66%

An in-depth introduction to the evolving fibromyalgia therapeutics landscape highlighting clinical complexity, treatment gaps, and strategic priorities

Fibromyalgia remains a clinically complex syndrome characterized by chronic widespread pain, fatigue, sleep disturbances, and cognitive symptoms that collectively drive significant functional impairment for patients and stress for care systems. Clinical heterogeneity and overlapping comorbidities such as mood disorders and chronic pain syndromes complicate diagnosis and therapeutic selection, which in turn elevates the importance of individualized care pathways and multi-modal management strategies. In practice, clinicians balance symptomatic pharmacologic options with non-pharmacologic interventions while seeking to minimize adverse effects and polypharmacy risks.

At the same time, evolving science has sharpened attention on central sensitization, neuroimmune interactions, and the role of dysregulated neurotransmission as targets for therapeutic innovation. Consequently, researchers and developers are redirecting efforts toward mechanism-aware candidates, repurposed agents with robust safety profiles, and adjunctive platforms that complement traditional pharmacotherapy. From a commercial perspective, stakeholders must reconcile clinical complexity with payer expectations and distribution realities, while ensuring that patient-reported outcomes and quality-of-life improvements are demonstrably integrated into product value propositions.

As the field moves forward, coordinated strategies that align clinical evidence generation, patient engagement, and stakeholder alignment will be essential for translating therapeutic promise into meaningful improvements in care delivery and patient functioning.

Transformative shifts reshaping fibromyalgia treatment through mechanism-focused therapeutics, digital care, adaptive clinical trials, and evolving payer engagement

The last several years have produced a series of transformative shifts that are changing how fibromyalgia therapeutics are developed, evaluated, and delivered. Scientific advances are moving the emphasis from broad symptomatic management to pathway-specific interventions informed by neurobiology, while adaptive trial designs and enriched enrolment strategies are accelerating the ability to test mechanism-based hypotheses in clinically relevant populations. Simultaneously, the rise of digital therapeutics and remote monitoring tools is expanding the portfolio of non-pharmacologic interventions that can be combined with drug therapies to deliver holistic care.

Regulatory agencies and payers are also evolving their expectations, increasingly focusing on patient-centric endpoints, real-world evidence, and outcomes that capture functional improvements rather than isolated symptom reduction. This shift has incentivized sponsors to design trials with composite measures and to engage early with payers to align on acceptable evidence packages. In parallel, advances in biomarkers and phenotyping are enabling more precise patient segmentation, which helps reduce heterogeneity in trial populations and improves signal detection for targeted therapeutics.

Taken together, these shifts create new opportunities for innovators to differentiate through evidence, for clinicians to personalize regimens, and for health systems to integrate multimodal care, but they also raise the bar for evidentiary rigor, cross-stakeholder coordination, and commercialization planning.

Evaluating how United States tariff measures in 2025 may reshape supply chains, procurement decisions, and development strategies for fibromyalgia therapeutics

Policy interventions such as tariff adjustments can exert material effects on the operational and strategic calculus for therapeutic development and deployment, and the United States tariff measures implemented in 2025 represent a notable variable for stakeholders in the fibromyalgia therapeutics ecosystem. These measures influence the cost and availability of active pharmaceutical ingredients, specialized excipients, medical devices used for neuromodulation or delivery, and laboratory reagents necessary for biomarker assays. As a result, sponsors and manufacturers must re-evaluate sourcing strategies and inventory practices to manage potential supply-chain volatility.

Moreover, procurement processes in hospitals and integrated delivery networks may shift in response to changed landed costs for imported components, prompting contract renegotiations and a renewed focus on supplier diversity. At the same time, manufacturers that rely on global contract manufacturing and international R&D partnerships may need to adjust operational footprints, either by identifying alternative suppliers or by increasing domestic capabilities to mitigate tariff exposure. These strategic responses have implications for product timelines, cost structures, and partner selection.

Importantly, the tariff environment also affects the competitive dynamics between branded and generic alternatives, since cost pressures can alter formulary positioning and negotiations with payers. Consequently, industry participants must adopt a proactive posture that incorporates scenario planning, supplier audits, and cross-functional coordination to preserve supply continuity and maintain alignment with clinical and commercial strategies.

Segmentation insights across drug class dynamics, administration routes, distribution channels, and end users to guide clinical and commercial decisions

Insights drawn from segmentation analysis reveal how clinical, commercial, and operational choices intersect across multiple axes that define the fibromyalgia therapeutics ecosystem. Based on drug class, the landscape encompasses Anticonvulsants, Selective Serotonin Reuptake Inhibitors, Serotonin And Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants; within those categories, Anticonvulsants are further characterized by branded and generic options, and the same branded-versus-generic dynamic applies to Selective Serotonin Reuptake Inhibitors, Serotonin And Norepinephrine Reuptake Inhibitors, and Tricyclic Antidepressants, which directly affects lifecycle planning and price competitiveness.

Based on route of administration, products are evaluated in the contexts of Oral, Parenteral, and Topical delivery, each route offering distinct adherence profiles, formulation challenges, and opportunities for differentiation, particularly when formulation science or novel delivery devices can drive superior tolerability or targeted pharmacokinetics. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy pathways each present unique contracting, inventory, and patient-access considerations; the growth of e-commerce and specialty fulfillment has begun to reshape dispensing behavior and patient convenience expectations.

Finally, based on end user, therapy utilization varies across Home Care, Hospital, and Specialty Clinics, with home-based management and remote monitoring increasingly prominent for chronic care pathways, while hospitals and specialty clinics continue to anchor acute interventions, diagnostics, and multidisciplinary care. Synthesizing these segmentation lenses supports targeted clinical development, pricing strategies, and channel-specific commercialization plans.

Regional insights on regulatory regimes, clinical adoption, reimbursement models, and operational priorities across global territories for fibromyalgia treatment

Regional dynamics materially influence development priorities, access strategies, and commercialization pathways for fibromyalgia therapeutics, and a regionally calibrated approach is essential. In the Americas, regulatory frameworks and payer negotiations emphasize outcomes and pharmacoeconomic assessments, while innovation hubs and established contract manufacturing networks support rapid product iteration and supply chain resilience. The Americas also exhibit strong uptake of digital health solutions and patient advocacy momentum, which can accelerate enrollment in decentralized trials and adoption of integrated care pathways.

In Europe, Middle East & Africa, heterogeneous regulatory regimes and reimbursement environments necessitate differentiated launch sequencing and bespoke value dossiers; pricing pressures in some European markets contrast with pockets of rapid adoption in specialty care settings, and the region's diverse healthcare architectures demand localized evidence generation and stakeholder engagement. Meanwhile, Asia-Pacific presents a mixed landscape where rapid clinical trial activity, growing domestic manufacturing capacity, and varied payer systems create both opportunities and complexities for market entry. In many Asia-Pacific markets, strategic partnerships with regional developers and local regulatory navigation are critical to securing access.

Across regions, cross-border collaboration, tailored payer dialogues, and adaptive evidence generation strategies enable sponsors to align clinical programs with local standards of care and reimbursement expectations while preserving global roadmap consistency.

Corporate and competitive insights on how innovators, specialty developers, contract manufacturers, and digital vendors shape fibromyalgia care strategies

Corporate positioning in the fibromyalgia therapeutics arena reflects an interplay between innovation-driven developers, specialty biotech ventures, contract manufacturing organizations, and emerging digital health vendors. Innovators are concentrating on differentiated mechanisms and improved tolerability profiles to achieve clinical differentiation, while specialty developers and platform companies pursue adjunctive approaches that can be combined with pharmacotherapy to address multidimensional symptom burden. Contract manufacturers and CDMOs are central to scaling complex formulations and ensuring supply reliability, and their capabilities increasingly factor into partner selection and contingency planning.

Digital vendors are partnering with clinical teams to embed remote monitoring, patient-reported outcome capture, and behavioral interventions into care pathways, which can strengthen value propositions to payers and providers. Across the value chain, strategic alliances, licensing deals, and selective M&A activity are common tactics to accelerate access to complementary assets, expand geographic reach, or acquire manufacturing capacity. At the same time, lifecycle management tactics such as new formulations, targeted indications, and enhanced labeling are being used to sustain commercial momentum in the face of generic competition.

To compete effectively, corporate leaders must synchronize R&D priorities with commercialization and access strategies, ensure rigorous evidence generation, and establish flexible manufacturing and distribution arrangements that can respond to regional and policy-driven disruptions.

Actionable recommendations for industry leaders to prioritize supply resilience, evidence-based development, payer alignment, and patient-centric commercialization approaches

Industry leaders should adopt a multi-pronged approach that strengthens supply resilience, advances evidence generation, and centers patient experience in commercialization plans. First, fortify supply chains by diversifying supplier bases for critical APIs and components, investing in strategic inventory buffers, and conducting regular supplier risk assessments to anticipate procurement disruptions. Second, prioritize development programs that integrate patient-reported outcomes and functional endpoints, use adaptive or enrichment trial designs where appropriate, and plan early interactions with regulators and payers to align on acceptable evidence packages.

Third, expand value propositions by pairing pharmacologic candidates with digital therapeutics, behavioral supports, or delivery innovations that improve adherence and functional outcomes, thereby enhancing the product's clinical and economic story. Fourth, strengthen payer engagement through outcomes-based contracting pilots, real-world evidence partnerships, and health economic modeling that clearly demonstrates the therapeutic's impact on utilization, quality of life, and total cost of care. Finally, invest in targeted commercial strategies that reflect segmentation realities: tailor messaging and channel approaches for hospital procurement, online pharmacy distribution, retail access, and specialty clinic relationships, and equip field teams with evidence-based tools to articulate differentiated value.

Taken together, these actions help organizations mitigate operational risks, accelerate adoption, and align therapeutic development with the needs of patients and health systems.

Detailed research methodology explaining data sources, expert engagements, real-world evidence techniques, and analytical rigor applied to fibromyalgia insights

The research underpinning these insights employed a mixed-methods design that triangulated qualitative expert input with quantitative evidence sources and document analysis to ensure analytical rigor and relevance. Primary research included structured interviews with clinical key opinion leaders, formulary decision makers, procurement specialists, and developers with active programs in fibromyalgia, providing perspective on real-world treatment patterns, evidence expectations, and operational constraints. Secondary sources comprised peer-reviewed clinical literature, regulatory filings, trial registries, and available public repositories of clinical and safety data to contextualize mechanistic and efficacy signals.

Supplementing these sources, real-world evidence techniques were applied where possible to interpret treatment utilization patterns and care pathways, and commercial intelligence informed assessments of distribution and channel dynamics. Analytical methods emphasized cross-validation across sources and sensitivity to regional regulatory nuances. Limitations of the methodology include variability in publicly available data granularity for certain therapeutic classes and the evolving nature of policy measures that can affect supply chain and reimbursement landscapes.

To support decision making, the methodology prioritized transparency regarding assumptions, provided appendices detailing source lists and interview profiles, and recommended ongoing evidence updates as new clinical and policy developments emerge.

Conclusive synthesis emphasizing integrated clinical, commercial, and policy actions to accelerate meaningful improvements in fibromyalgia patient care outcomes

In conclusion, the fibromyalgia therapeutics landscape is at an inflection point characterized by deeper mechanistic understanding, evolution in evidence expectations, and shifting operational dynamics driven by policy and supply considerations. Effective responses require aligning therapeutic development with patient-centered endpoints, investing in complementary digital and behavioral solutions, and maintaining supply chain agility to withstand policy-induced disruptions. Clinicians, payers, and developers must collaborate to define meaningful outcome measures and to design evidence-generation plans that support both regulatory approval and payer acceptance.

Strategically, organizations that integrate clinical differentiation, robust real-world evidence strategies, and tailored regional approaches will be best positioned to navigate competitive pressures and access constraints. Operational readiness-manifested through diversified sourcing, manufacturing flexibility, and proactive payer engagement-will be equally critical to sustaining product availability and value realization. Ultimately, delivering improved patient outcomes will depend on coordinated action across R&D, commercial, regulatory, and health system stakeholders, with an emphasis on transparent evidence, measurable functional benefits, and scalable care models.

Stakeholders who adopt these integrated approaches can more effectively translate therapeutic innovation into tangible improvements for patients living with fibromyalgia.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Fibromyalgia Therapeutics Market, by Drug Class

  • 8.1. Anticonvulsants
    • 8.1.1. Branded
    • 8.1.2. Generic
  • 8.2. Selective Serotonin Reuptake Inhibitors
    • 8.2.1. Branded
    • 8.2.2. Generic
  • 8.3. Serotonin And Norepinephrine Reuptake Inhibitors
    • 8.3.1. Branded
    • 8.3.2. Generic
  • 8.4. Tricyclic Antidepressants
    • 8.4.1. Branded
    • 8.4.2. Generic

9. Fibromyalgia Therapeutics Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Parenteral
  • 9.3. Topical

10. Fibromyalgia Therapeutics Market, by Distribution Channel

  • 10.1. Hospital Pharmacy
  • 10.2. Online Pharmacy
  • 10.3. Retail Pharmacy

11. Fibromyalgia Therapeutics Market, by End User

  • 11.1. Home Care
  • 11.2. Hospital
  • 11.3. Specialty Clinics

12. Fibromyalgia Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Fibromyalgia Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Fibromyalgia Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Fibromyalgia Therapeutics Market

16. China Fibromyalgia Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Amgen Inc.
  • 17.7. Amicus Therapeutics
  • 17.8. Astellas Pharma Inc
  • 17.9. AstraZeneca plc
  • 17.10. Bayer AG
  • 17.11. Biogen Inc.
  • 17.12. BioMarin Pharmaceutical Inc
  • 17.13. C.H. Boehringer Sohn AG & Co. KG
  • 17.14. Eli Lilly and Company
  • 17.15. Gilead Sciences, Inc.
  • 17.16. GlaxoSmithKline (GSK)
  • 17.17. Jazz Pharmaceuticals plc
  • 17.18. Johnson & Johnson Services, Inc.
  • 17.19. Kyowa Kirin Co, Ltd
  • 17.20. Merck & Co., Inc.
  • 17.21. Novartis AG
  • 17.22. Pfizer inc.
  • 17.23. Regeneron Pharmaceuticals, Inc.
  • 17.24. Roche Holding AG
  • 17.25. Sanofi S.A.
  • 17.26. Sarepta Therapeutics, Inc.
  • 17.27. Takeda Pharmaceutical Company
  • 17.28. Teva Pharmaceutical Industries Ltd.
  • 17.29. The Bristol-Myers Squibb Company
  • 17.30. Vertex Pharmaceuticals Incorporated
  • 17.31. Viatris inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 158. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 159. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 161. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 162. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GCC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 185. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 186. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 189. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 190. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. G7 FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 194. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 195. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 197. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 198. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 199. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 200. NATO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTICONVULSANTS, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)